Efficacy and safety of Bempedoic acid in patients with hypercholesterolemia
Posted at2022-01-06
Efficacy and safety of Bempedoic acid in patients with hypercholesterolemia
The researchers systematically searched PubMed, Web of Science, Scopus and EMBASE databases. Effect outcomes were expressed as percentage changes in total cholesterol, low-density lipoprotein cholesterol, triglycerides, high-density lipoprotein cholesterol, apolipoprotein B, non-high-density lipoprotein cholesterol, and high-sensitivity C-reactive protein (HS-CRP) between BA and control users (mean difference with 95% CI [MD]).
This analysis included seven studies (2767 ba-treated patients and 1469 controls) in which low density lipoprotein cholesterol (MD, -17.5%; 95% CI, -22.9% to -12.0%), total cholesterol (MD, -10.9%; 95% CI, -13.3% to -8.5%), non-HIGH-DENSITY lipoprotein cholesterol (MD, -12.3%; 95% CI, -15.3% to -9.20%), apolipoprotein B (MD, − 10.6%; 95% CI, -13.2% to -8.02%) and hs-CRP (MD, − 13.2%; 95% CI, -16.7% to − 9.79%) decreased significantly. Compared with the control group, subjects treated with BA reported higher rates of treatment discontinuities due to adverse events, gout episodes, and elevated uric acid. On the other hand, the incidence of diabetes was lower in patients treated with BA than in the control group.
In conclusion, BA significantly reduced LDL cholesterol, total cholesterol, non-HIGH-DENSITY lipoprotein cholesterol, apolipoprotein B, and hs-CRP compared with standard therapy.